v3.26.1
Segment Reporting - Summary of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Research and development expenses $ (30,749)   $ (22,882)   $ (58,709) $ (46,225)
General and Administrative [1] (17,320)   (5,731)   (24,226) (11,423)
Other Segment Items [2] 2,432   1,594   3,614 3,146
Net loss (45,637) $ (33,685) (27,019) $ (27,483) (79,322) (54,502)
Clinical, Preclinical, and R&D Operations            
Segment Reporting Information [Line Items]            
Research and development expenses [1] (18,314)   (16,811)   (37,680) (33,197)
Chemistry, Manufacturing and Controls            
Segment Reporting Information [Line Items]            
Research and development expenses [1] $ (12,435)   $ (6,071)   $ (21,030) $ (13,028)
[1] Includes depreciation expense directly allocated to respective activities.
[2] Other segment items primarily include interest and accretion income, realized gains and losses, and income taxes.